Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Autor: James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gert, Brawley, Chris D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., Bono, Johann S., Montana, Carlos Diaz, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominic R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W.S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob, Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K.B., Sydes, Matthew R.

Publikováno v: James, N D, Clarke, N W, Cook, A, Ali, A, Hoyle, A P, Attard, G, Brawley, C D, Chowdhury, S, Cross, W R, Dearnaley, D P, Bono, J S, Montana, C D, Gilbert, D, Gillessen, S, Gilson, C, Jones, R J, Langley, R E, Malik, Z I, Matheson, D J, Millman, R, Parker, C C, Pugh, C, Rush, H, Russell, J M, Berthold, D R, Buckner, M L, Mason, M D, Ritchie, A WS, Birtle, A J, Brock, S J, Das, P, Ford, D, Gale, J, Grant, W, Gray, E K, Hoskin, P, Khan, M M, Manetta, C, McPhail, N J, O'Sullivan, J M, Parikh, O, Perna, C, Pezaro, C J, Protheroe, A S, Robinson, A J, Rudman, S M, Sheehan, D J, Srihari, N N, Syndikus, I, Tanguay, J, Thomas, C W, Vengalil, S, Wagstaff, J, Wylie, J P, Parmar, M KB & Sydes, M R 2022, ' Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476) ', International Journal of Cancer . https://doi.org/10.1002/ijc.34018

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multi-arm, multi-stage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d41e4f972431efac3e44597e81d1a4a
https://pure.qub.ac.uk/en/publications/3adddebe-1d1a-4134-8495-5f087a1fee9e

Prostate brachytherapy post-implant dosimetry: A comparison between higher and lower source density

Autor: Thomas, Carys W., Kruk, Alexandra, McGahan, Colleen E., Spadinger, Ingrid, Morris, W. James

Publikováno v: In Radiotherapy and Oncology 2007 83(1):18-24

Influence of segmental urethral dosimetry on urinary morbidity in prostate brachytherapy

Autor: Thomas, Carys W., Keyes, Mira, Liu, Mitchell, Moravan, Veronika

Publikováno v: In Brachytherapy 2007 6(2):91-92

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Autor: James ND; Institute of Cancer Research, London, UK., Clarke NW; The Departments of Surgery & Urology, The Christie & Salford Royal Hospitals, Manchester, UK., Cook A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Ali A; The Christie NHS Foundation Trust, Manchester, UK., Hoyle AP; Salford Royal HS Foundation Trust, Manchester, UK., Attard G; UCL Cancer Institute, University College London, London, UK., Brawley CD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Chowdhury S; Guy's, King's, & St. Thomas' Hospitals, and Sarah Cannon Research Institute, London, UK., Cross WR; St James University Hospital, Leeds, UK., Dearnaley DP; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK., de Bono JS; Institute of Cancer Research, London, UK., Diaz-Montana C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Gilbert D; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Gillessen S; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland., Gilson C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.; Royal Marsden Hospital, London, UK., Jones RJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK., Langley RE; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Malik ZI; Radiotherapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Liverpool, L7 8YA, UK., Matheson DJ; School of Allied Health and Midwifery, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, WS1 3BD, UK., Millman R; (PPI) c/o MRC CTU at UCL, London, UK., Parker CC; Uro-Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK., Pugh C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Rush H; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.; Guys and St Thomas' NHS Foundation Trust, London, UK., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.; Beatson West of Scotland Cancer Centre, Glasgow, UK., Berthold DR; Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland., Buckner ML; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Mason MD; Cardiff University, School of Medicine, Cardiff, UK., Ritchie AWS; Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK., Birtle AJ; Rosemere Cancer Centre, Lancashire Teaching Hospitals & University of Manchester, University of Central Lancashire, Lancashire, UK., Brock SJ; University Hospital Dorset, Bournemouth, UK., Das P; Department of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK., Ford D; City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham, UK., Gale J; Portsmouth Hospitals University Trust, Portsmouth, UK., Grant W; Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK., Gray EK; Musgrove Park Hospital, Taunton, UK., Hoskin P; Mount Vernon Cancer Centre, Northwood, UK., Khan MM; Department of Oncology Castle Hill Hospital, Hull, UK.; Scarborough General Hospital, Scarborough, UK., Manetta C; Brighton and Sussex University Hospitals NHS Trust, Brighton, UK., McPhail NJ; Department of Clinical Oncology, Raigmore Hospital, Inverness, UK., O'Sullivan JM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK., Parikh O; Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK., Perna C; Royal Surrey NHS Foundation Trust, Guildford, UK., Pezaro CJ; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Protheroe AS; Oxford University Hospitals NHS Foundation Trust, Oxfordshire, UK., Robinson AJ; Sussex Cancer Centre, Brighton, UK., Rudman SM; Guys and St Thomas' NHS Foundation Trust, London, UK., Sheehan DJ; Royal Devon & Exeter NHS Foundation Trust, Exeter, UK., Srihari NN; Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK., Syndikus I; Radiotherapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Liverpool, L7 8YA, UK., Tanguay JS; Velindre Cancer Centre, Cardiff, UK., Thomas CW; Kent Oncology Centre, Maidstone, Kent, UK., Vengalil S; University Hospital North Midlands NHS Trust, Staffordshire, UK., Wagstaff J; Swansea University and the South West UK Cancer Centre, Swansea, UK., Wylie JP; The Christie NHS Foundation Trust, Manchester, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.

Publikováno v: International journal of cancer [Int J Cancer] 2022 Aug 01; Vol. 151 (3), pp. 422-434. Date of Electronic Publication: 2022 May 16.